Avedro Initiates Keraflex (R) Clinical trials for the treatment of keratoconus KXL

Aug 20th, 2012 by admin in doctor

Results of the initial treatment of the first group of Keraflex KXL patients, treated by Prof. Omer Faruk Yilmaz, MD, Beyoglu Eye Hospital research and training in Istanbul, Turkey, were presented in Leipzig by Prof. John Marshall, PhD, FRCPath, FRCOphthal , Emeritus Professor of Ophthalmology at King College London, and Dr.At the 5th International Congress of Cross Linking for keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging clinical results in early treatment of keratoconus, a progressive disease of the cornea of ​​the eye. The procedure, known as Keraflex KXL is no incision and reshapes the cornea without removing any tissue.

Dr. Our experience shows in the early improvements in keratoconus corneas that we saw with previous technologies. This should help to improve vision in patients with keratoconus, a cornea problem that is difficult to correct and improve the use of contact lenses and vision with glasses. We hope that Keraflex can help avoid corneal transplants in many patients that otherwise might not have alternatives.

Commenting on the presentations, David Muller, PhD, President and CEO of Avedro said: It was clear that the discerning conference attendees universally welcomed the new data and were equally excited about the promise of technology for their keratoconus patients who are currently facing limited treatment options in the refractive index. Keraflex KXL While it is being tested clinically for the correction of myopia since the beginning of the year, the data presented in Leipzig by another study that began in November keratoconus. visually debilitating nature of keratoconus and the lack of refractive correction alternative for patients with keratoconus have led the company to accelerate its efforts to make Keraflex KXL commercially available for the treatment of patients with keratoconus in Europe as soon as the company receives the its CE mark.

Charles D. Howell, MD, Professor of Medicine, University of Maryland School of Medicine, said the NIH study of liver transplant HBV infection in an editorial also published in the September issue of Liver Transplantation. Dr. Howell cited earlier studies where the results were different across races.
‘The study of organ procurement and transplantation network data from 1994-1998 found that African-Americans 18-70 were under-represented in the list of beneficiaries of the liver UNOS waiting.

No Comments


Comments have been closed for this post.